Skip to main content
Article thumbnail
Location of Repository

A Hypomorphic Vasopressin Allele Prevents Anxiety-Related Behavior

By Mirjam Bunck, Ludwig Czibere, Charlotte Horvath, Cornelia Graf, Elisabeth Frank, Melanie S. Keßler, Chris Murgatroyd, Bertram Müller-Myhsok, Mariya Gonik, Peter Weber, Benno Pütz, Patrik Muigg, Markus Panhuysen, Nicolas Singewald, Thomas Bettecken, Jan M. Deussing, Florian Holsboer, Dietmar Spengler and Rainer Landgraf
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2006). A periodic pattern of mRNA secondary structure created by the genetic code.
  2. (2003). ABCB1 (MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary-adrenocortical system: implications for affective disorder.
  3. (1999). Activation of the insulin-like growth factor-binding protein-5 promoter in osteoblasts by cooperative E box, CCAAT enhancer-binding protein, and nuclear factor-1 deoxyribonucleic acidbinding sequences.
  4. (2008). Acute stress regulation of neuroplasticity genes in mouse hippocampus CA3 area - Possible novel signalling pathways.
  5. (2008). Advances in vasopressin and oxytocin - from genes to behaviour to disease.
  6. (2004). Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin.
  7. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(2Delta Delta C(T)) Method.
  8. (2002). Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.
  9. (1978). Behavioural despair’’ in rats and mice: strain differences and the effects of imipramine.
  10. (2006). Brain activation pattern induced by stimulation of L-type
  11. (2007). Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I.
  12. (2008). Central vasopressin and oxytocin release: regulation of complex social behaviours.
  13. (2007). Centrally released oxytocin mediates matinginduced anxiolysis in male rats.
  14. (2007). Diabetes insipidus and, partially, low anxiety-related behaviour are linked to a SNPassociated vasopressin deficit in LAB mice.
  15. (2003). Diabetes insipidus.
  16. (2008). Dissociation of the anxiolytic-like effects of Avpr1a and Avpr1b receptor antagonists in the dorsal and ventral hippocampus.
  17. (2004). Do the genetic or environmental determinants of anxiety and depression change with age? A longitudinal study of Australian twins.
  18. (2008). Epigenetic mechanisms and the transgenerational effects of maternal care.
  19. (2004). Epigenetic regulation of mammalian genomic imprinting.
  20. (2007). Ets-2 and C/EBP-beta are important mediators of ovine trophoblast Kunitz domain protein-1 gene expression in trophoblast.
  21. (2007). Expression profiling identifies the CRH/CRH-R1 system as a modulator of neurovascular gene activity.
  22. (2007). Genetics of behavioural domains across the neuropsychiatric spectrum; of mice and men.
  23. (2004). Global burden of depressive disorders in the year
  24. (2005). Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety.
  25. (2007). Identification of polymorphisms in the human 11beta-hydroxysteroid dehydrogenase type 2 gene promoter: functional characterization and relevance for salt sensitivity.
  26. (2004). Impaired repression at a vasopressin promoter polymorphism underlies overexpression of vasopressin in a rat model of trait anxiety.
  27. (2007). Impaired social interaction and reduced anxiety-related behavior in vasopressin V1a receptor knockout mice.
  28. (2005). Integrating QTL and high-density SNP analyses in mice to identify Insig2 as a susceptibility gene for plasma cholesterol levels.
  29. (1973). Isolated removal of hypothalamic or other brain nuclei of the rat.
  30. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.
  31. (2000). Major depressive disorder.
  32. (2008). Mice selected for high versus low stress reactivity: A new animal model for affective disorders.
  33. (2006). Minor disturbances in central nervous system function in familial neurohypophysial diabetes insipidus.
  34. (1999). Molecular genetics of mood disorders.
  35. (2004). Multivariate analysis of quantitative trait loci influencing variation in anxiety-related behavior in laboratory mice.
  36. (2002). Neurobiology of depression.
  37. (2001). Neuropeptides and anxiety-related behavior.
  38. (1994). Nitric oxide synthase increases in hypothalamic magnocellular neurons after salt loading in the rat. An immunohistochemical and in situ hybridization study.
  39. (2001). Nuclear factor 1 family members mediate repression of the BK virus late promoter.
  40. (2001). Oxytocin and vasopressin as candidate genes for psychiatric disorders: lessons from animal models.
  41. (2004). Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS).
  42. (2004). Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice.
  43. (2003). Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant
  44. (2003). Regulatory domains in the intergenic region of the oxytocin and vasopressin genes that control their hypothalamusspecific expression in vitro.
  45. (2000). Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders.
  46. (2007). Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats.
  47. (1984). Structure and comparison of the oxytocin and vasopressin genes from rat.
  48. (1993). The aberrant vasopressin precursor in rats with central diabetes insipidus (Brattleboro rats). Response to stimuli.
  49. (2005). The central vasopressinergic system: examining the opportunities for psychiatric drug development.
  50. (2006). The genetic basis of emotional behaviour in mice.
  51. (2006). The involvement of the vasopressin system in stress-related disorders.
  52. (2001). The mouse brain in stereotaxic coordinates. 2nd Edition ed.
  53. (1985). The tail suspension test: a new method for screening antidepressants in mice.
  54. (1987). The use of a plus-maze to measure anxiety in the mouse.
  55. (2005). The V1a vasopressin receptor is necessary and sufficient for normal social recognition: a gene replacement study.
  56. (1998). The vasopressin deficient Brattleboro rats: a natural knockout model used in the search for CNS effects of vasopressin.
  57. (2008). The vasopressin system - from antidiuresis to psychopathology.
  58. (1995). V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats.
  59. (2002). Vasopressin as a target for antidepressant development: an assessment of the available evidence.
  60. (2003). What good is genomic imprinting: the function of parent-specific gene expression.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.